Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Jen Lamppa
Advertisement
Jen Lamppa is VP of commercial strategy at Inovalon.
Articles by Jen Lamppa
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
2
The Realistic Path to Making MFN Pricing Permanent
3
The Battle to Own the GLP-1 Patient Journey
4
Roundup: Orbis Enters $1.4 Billion Partnership with Novo, Dualitas Therapeutics Enters Research collaboration with Roche, Aethlon Medical Merges with North Immunology
5